Novartis said an important new drug for treating heart failure has been granted an accelerated review by European authorities, improving its chances of approval in Europe next year.
WSJ.com: US Business, Wall Street Journal: Business
Fri, 11/28/2014 - 12:35am
Novartis said an important new drug for treating heart failure has been granted an accelerated review by European authorities, improving its chances of approval in Europe next year.